Literature DB >> 7107606

Metabolism of squalene in human fat cells. Demonstration of a two-pool system.

R Tilvis, P T Kovanen, T A Miettinen.   

Abstract

Human adipose tissue has been shown to contain exceptionally high concentrations of squalene. In the present experiments, it was shown that most of adipose tissue squalene is located in the fat cells. Of this squalene, 80% is located in the central neutral lipid droplet and 20% is bound to the microsomal membranes. Upon incubation of isolated fat cells with radiolabeled substrates, both the microsomal and the droplet squalene became labeled. The specific activity of microsomal squalene increased faster than that of droplet squalene. In addition, the microsomal squalene quickly equilibrated to a maximal specific activity, whereas the droplet squalene showed a steady increase in specific activity. These observations indicate rapid turnover of microsomal squalene and slow turnover of droplet squalene. Moreover, they reflect intracellular transfer of labeled squalene from microsomes to the lipid droplet. During a 3-hour incubation of fat cells with labeled substrates, 90% of the newly formed labeled squalene was transferred to the lipid droplet and only 10% was converted into cholesterol. The results demonstrate that adipocyte squalene can be segregated anatomically and functionally into two distinct pools: a small metabolically active pool in the microsomal membranes where squalene is synthesized and a large metabolically inactive pool in the fat droplet where squalene is stored. The intracellular transfer of de novo synthesized squalene into the fat droplet of fat cells is one mechanism of squalene accumulation in adipose tissue.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107606

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82.

Authors:  Robert Lafyatis; Julio C Mantero; Jessica Gordon; Nina Kishore; Mary Carns; Howard Dittrich; Robert Spiera; Robert W Simms; John Varga
Journal:  J Invest Dermatol       Date:  2017-08-12       Impact factor: 8.551

2.  A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines.

Authors:  Million A Tegenge; Robert J Mitkus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-04       Impact factor: 2.745

3.  Hepatic subcellular distribution of squalene changes according to the experimental setting.

Authors:  Roberto Martínez-Beamonte; Olga Alda; Teresa Sanclemente; María J Felices; Sara Escusol; Carmen Arnal; Luis V Herrera-Marcos; Sonia Gascón; Joaquín C Surra; Jesús Osada; Mª Jesús Rodríguez-Yoldi
Journal:  J Physiol Biochem       Date:  2018-02-22       Impact factor: 4.158

4.  Amaranth oil application for coronary heart disease and hypertension.

Authors:  Danik M Martirosyan; Lidia A Miroshnichenko; Svetlana N Kulakova; Ala V Pogojeva; Vladimir I Zoloedov
Journal:  Lipids Health Dis       Date:  2007-01-05       Impact factor: 3.876

5.  Pharmacokinetics, biodistribution and metabolism of squalenoyl adenosine nanoparticles in mice using dual radio-labeling and radio-HPLC analysis.

Authors:  Alice Gaudin; Sinda Lepetre-Mouelhi; Julie Mougin; Martine Parrod; Grégory Pieters; Sébastien Garcia-Argote; Olivier Loreau; Jordan Goncalves; Hélène Chacun; Yann Courbebaisse; Pascal Clayette; Didier Desmaële; Bernard Rousseau; Karine Andrieux; Patrick Couvreur
Journal:  J Control Release       Date:  2015-06-16       Impact factor: 9.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.